Mr. Hermes Chan reports

MEDMIRA ANNOUNCES EXCLUSIVE DISTRIBUTION AGREEMENT WITH TRIMEDIC INC. FOR CANADA

Medmira Inc. has signed an exclusive distribution agreement with Trimedic Inc. for the Canadian market. This partnership allows Medmira to expedite its growth in the Canadian market with the recently Health Canada-approved Multiplo TP/HIV rapid antibody test and its Reveal G4 HIV-1/2 rapid antibody test. Both products have been granted Class 4 medical device licences, the highest regulatory classification for medical diagnostics in Canada.

Trimedic is a leading supplier and distributor of medical supplies in Canada since 1986. As one of Canada's largest providers of point-of-care diagnostic, Trimedic is focused on expanding access to laboratory quality tests at point of care. Ultimately reducing the wait times to receive accurate results to key health indicators. Trimedic's key strategy is to enable a decentralize diagnostic testing and disease monitoring.

"With the recent Health Canada approvals for our Multiplo TP/HIV and Reveal G4 HIV rapid tests, we are excited to bring fast and reliable testing solutions to Canada, addressing an urgent need in the market. As we prepare for the upcoming approvals of new and innovative products, particularly our unique syphilis tests, it is essential to have an experienced and focused distribution partner. Trimedic, with its knowledgeable team and well-established network, is the ideal partner to support Medmira's growth and expansion in Canada," said Hermes Chan, chief executive officer of Medmira. "This partnership allows us to expand in the growing STI rapid test market while enabling Medmira to focus on its core strengths, including product development, regulatory compliance and manufacturing."

Trimedic has been a pioneer in various point-of-care products such as in the field of harm reduction and women's health which are key markets for Medmira's product portfolio. With the already approved products on hand and a number of additional products in the review process and clinical trials, the company expects to further expand on its offering. As a result this partnership can further contribute to provide high quality rapid tests in Canada.

The latest data from the Public Health Agency of Canada, shows that new HIV diagnoses soared more than 35 per cent from 2022 to 2023, with rates in Manitoba rising by more than 40 per cent. In Saskatchewan, the rate of HIV was 19.4 per 100,000 people, more than three times the national rate. In 2022, there were 13,953 reported syphilis cases, with rates increasing by 109 per cent compared with 2018, and with congenital syphilis cases seeing a 7-per-cent increase from 2021 and a 599-per-cent increase from 2018. With the rising cases, particularly in underserved and remote communities, the MultiploTP/HIV provides an essential testing device to help reach the undiagnosed living with HIV and/or syphilis.

About Medmira Inc.

Medmira is a leading developer and manufacturer of rapid vertical flow diagnostics. The company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as HIV, syphilis, hepatitis and SARS-CoV-2, in just three easy steps. The company's tests are sold globally under the Reveal, RevealCOVID-19, Multiplo and Miriad brands. Based on its patented rapid vertical flow technology, Medmira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. Medmira's corporate offices and manufacturing facilities are located in Halifax, N.S., Canada.

We seek Safe Harbor.